Nahid Saghir
UCB Pharma (United Kingdom)(GB)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Protein Kinase Regulation and GTPase Signaling, Biochemical and Molecular Research, Phagocytosis and Immune Regulation, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer(2008)741 cited
- → Exploring the specificity of the PI3K family inhibitor LY294002(2007)457 cited
- → Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases(2007)349 cited
- → Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941(2009)271 cited
- → Characterisation and Properties of an Intracellular Lipid‐Binding Protein from the Tapeworm Moniezia expansa(1997)52 cited
- → A new diagnostic tool for neurocysticercosis is a member of a cestode specific hydrophobic ligand binding protein family1(2000)34 cited
- Targeting PI3KC2β impairs proliferation and survival in acute leukemia, brain tumours and neuroendocrine tumours.(2012)
- → Biochemical characterisation of a hydrophobic ligand binding protein from the tapeworm Hymenolepis diminuta(2001)25 cited
- → Preparation and evaluation of trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors. 3-Hydroxyphenol analogues and bioisosteric replacements(2010)21 cited
- The discovery of GDC-0941: A potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer(2008)